přejít na obsah
Long-Term Consequences of Drugs on the Paediatric Cardiovascular System
ZavřítNáhled dokumentu
Probíhá kontrola...

Long-Term Consequences of Drugs on the Paediatric Cardiovascular System

Autor Elizabeth HausnerMonica FiszmanJoseph HanigPatricia HarlowGwen ZornbergVšichni autoři
Vydavatel: Adis International Limited
Vydání/formát: Článek Článek : English
Zdroj:Drug Safety, 31, no. 12 (2008): 1083-1096
Databáze:ArticleFirst
Jiné databáze: MEDLINEElsevierBritish Library Serials
Hodnocení:

(ještě nehodnoceno) 0 zobrazit recenze - Buďte první.

Více podobných

 

&AllPage.SpinnerRetrieving;

Vyhledat exemplář v knihovně

&AllPage.SpinnerRetrieving; Vyhledávání knihoven, které vlastní tento dokument...

Detaily

Typ dokumentu: Article
Všichni autoři/tvůrci: Elizabeth Hausner; Monica Fiszman; Joseph Hanig; Patricia Harlow; Gwen Zornberg; Solomon Sobel
ISSN:0114-5916
Poznámka o jazyku: English
Jednoznačný identifikátor: 365863444
Ocenění:

Recenze

Recenze vložené uživatelem
Nahrávání recenzí GoodReads...
Přebírání recenzí DOGO books...

Štítky

Štítky všech uživatelů (1)

Zobrazit nejoblíbenější štítky jako: seznam štítků | tag cloud

  • good  (podle 1 osoba)

Podobné dokumenty

Seznamy uživatele s tímto dokumentem (1)

Potvrdit tento požadavek

Tento dokument jste si již vyžádali. Prosím vyberte Ok pokud chcete přesto v žádance pokračovat.

Propojená data


<http://www.worldcat.org/oclc/365863444>
library:oclcnum"365863444"
owl:sameAs<info:oclcnum/365863444>
rdf:typeschema:Article
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:creator
schema:datePublished"2008-12-11"
schema:description"Many pharmacological and toxicological actions of drugs in children cannot be fully predicted from adult clinical experience or from standard non-clinical toxicology studies. Numerous drugs have direct or indirect pharmacological effects on the heart and are prescribed for children of all ages. Toxicity or secondary effects may be immediate or delayed for years after drug exposure has ceased. Originally, the aim of this review was to compile information on the effect of specific drugs on the post-natal development of the cardiovascular system and to examine long-term follow-up of the use of cardio-active drugs in children. The limited database of published information caused the original question to evolve into an examination of the medical literature for three areas of information: (i) whether vulnerable developmental windows have been identified that reflect the substantial functional development that the cardiovascular system undergoes after birth; (ii) what is known about pharmacological perturbation of development; and (iii) what the likelihood is of drug exposure during childhood. We examined different scenarios for exposure including random, isolated exposure, conditions historically associated with adults, primary or secondary cardiac disease, psychiatric and neurological conditions, asthma, cancer and HIV. Except for random, isolated drug exposures, each category of possible exposure contained numerous drugs known to have either primary or secondary effects on the cardiovascular system or to influence factors associated with atherosclerosis. It is likely that a significant number of children will be prescribed drugs having either direct or indirect effects upon the immature cardiovascular system. A confounding factor is the simultaneous use of over-the-counter medications and herbal or nutraceutical preparations that a patient, parent or guardian does not mention to a prescribing physician. Metabolism is also important in assessing drug effects in children. Differences in body water : body fat ratio, age-related gastrointestinal absorption, distribution, excretion, renal function and drug metabolizing capabilities make it possible for children to have a different metabolite profile for a drug compared with adults. There is little examination of drug effects on the interdependent processes of cardiac maturation and less examination of metabolite effects. It is difficult to identify delayed toxicities in children as these adverse events may take years to manifest with many patients lost to follow-up. Clearly this is an area of study where intermediate endpoints and surrogate markers would be of great benefit. Pharmacogenomics may be useful in providing markers of increased risk or susceptibility. A perspective must be kept in balancing the possibility of a problem with the very real benefits that many children experience from the use of these pharmaceuticals."
schema:exampleOfWork<http://worldcat.org/entity/work/id/159255745>
schema:inLanguage"en"
schema:isPartOf
schema:name"Long-Term Consequences of Drugs on the Paediatric Cardiovascular System"
schema:pageStart"1083"
schema:publisher
schema:url

Content-negotiable representations

Zavřít okno

Prosím přihlaste se do WorldCat 

Nemáte účet? Můžete si jednoduše vytvořit bezplatný účet.